Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Exhibit 10.15
SCREENING AGREEMENT
This Screening Agreement (the "Agreement") is made as of August 23, 1999
(the "Effective Date"), by and between Tularik Inc., a Delaware corporation with
its offices at Xxx Xxxxxxxxx Xxxxx, Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx 00000
("Tularik") and Japan Tobacco Inc., a Japanese corporation with its offices at
JT Xxxxxxxx, 0-0 Xxxxxxxxx, 0- Xxxxx, Xxxxxx-Xx, Xxxxx 000-0000, Xxxxx ("JT").
Recitals
Whereas, Tularik possesses a library (the "Tularik Library") of chemically
diverse, pre-plated compounds acquired from public sources (the "Compounds") and
is able to screen the Tularik Library employing Tularik's proprietary screening
technology (the "Screening Technology"); and
Whereas, JT has certain drug targets (the "JT Targets") and assays
associated therewith (the "JT Assays") against which it desires that Tularik
screen selected Compounds from the Tularik Library; and
Whereas, Tularik desires to apply the Screening Technology to the Tularik
Library in order to identify and supply to JT those Compounds that are most
likely to show activity with respect to the JT Targets and therefore may lead to
candidates for drug development;
Now, Therefore, in consideration of the foregoing premises and the
covenants set forth below, the Parties hereby agree as follows:
1. Definitions.
1.1 "Affiliate" shall mean any corporation or other business entity that
during the term of this Agreement controls, is controlled by or is under common
control with JT or Tularik but only for so long as such entity controls, is
controlled by or is under common control with JT or Tularik. For this purpose,
control means the possession of the power to direct or cause the direction of
the management and the policies of an entity whether through ownership directly
or indirectly of over fifty percent (50%) of the stock entitled to vote, and for
non-stock organizations, the right to receive over fifty percent (50%) of the
profits by contract or otherwise, or if not meeting the preceding requirements,
any company owned or controlled by or owning or controlling JT or Tularik at the
maximum control or ownership right permitted in a country where such company
exists. Notwithstanding the foregoing, [ * ].
1.2 "Compounds" shall have the meaning given in the first recital.
1.3 "Confidential Information" shall have the meaning given in Section
6.1.
1.4 "Control" or "Controlled" shall mean possession by a Party of the
ability to grant a license or sublicense in accordance with the terms of this
Agreement, and without violating the terms of any agreement by such Party with a
Third Party.
1.5 "Disclosing Party" shall have the meaning given in Section 6.1.
1.6 "Eligible Compounds" shall mean High Activity Compounds or Compounds
that are not High Activity Compounds but for which payments are made by JT
pursuant to Section 4.3.
1.7 "FDA" shall mean the United States Food and Drug Administration, or
any successor organization.
1.8 "Field" shall mean prevention or treatment of human disease.
1.9 "First Commercial Sale" means, with respect to any Product, the first
sale for end use of such Product after receipt of the requisite regulatory
approval.
1.10 "High Activity Compound" shall mean a Compound: (a) identified
pursuant to the Screening Program; and (b) that [ * ].
1.11 "High Throughput-Ready Protocol" shall mean a protocol that describes
the procedure for screening any JT Assay that is consistent with a high
throughput screening format.
1.12 "High Throughput Validation Data" shall mean data with respect to a
JT Assay demonstrating: (a) [ * ], (b) [ * ] and (c) [ * ].
1.13 "IND" shall mean an Investigational New Drug application, as defined
in FDA regulations, as amended from time to time.
1.14 "Initial Compounds" shall have the meaning given in Section 2.2.2.
1.15 "Initial Results" shall have the meaning given in Section 2.2.3.
1.16 "Inventions" shall mean either JT Inventions or Tularik Inventions.
1.17 "Joint Technology" shall have the meaning given in Section 5.1.2.
1.18 "JT Assays" shall have the meaning given in the second recital.
1.19 "JT Inventions" shall have the meaning given in Section 5.1.1.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
2
1.20 "JT Know-How" shall mean all ideas, inventions, data, instructions,
processes, formulas, expert opinion and information, owned or Controlled in
whole or part by JT by license, assignment or otherwise, in each case, necessary
or useful for the screening of the JT Assays that is within the Control of JT
during the Screening Program Term, excluding JT Patent Rights.
1.21 "JT Patent Rights" shall mean Patent Rights owned, licensed or
Controlled by JT (including its Affiliates, licensors or its licensees) that
relate to the JT Targets or the JT Assays.
1.22 "JT Targets" shall have the meaning given in the second recital.
1.23 "JT Technology" shall mean JT Patent Rights and JT Know-How.
1.24 "License Commencement Date" shall mean the date on which a particular
Eligible Compound is identified.
1.25 "License Term" shall mean the period commencing on the License
Commencement Date and ending on a country-by-country and Product-by-Product
basis on the later to occur of: (i) [*] after the First Commercial Sale of such
Product in such country by JT, its Affiliates or Sublicensees; or (ii) the
expiration of the last to expire issued patent within the Tularik Inventions
containing any claim that would be infringed by a Third Party by making, using
or selling the applicable Product in the applicable country.
1.26 "NDA" shall mean a New Drug Application, as defined in FDA
regulations, as amended from time to time.
1.27 "Party" shall mean either Tularik or JT.
1.28 "Patent Rights" shall mean all U.S. or foreign jurisdiction
(including the European Patent Convention) patent applications, including any
regular, or provisional applications and any continuation (in whole or in part),
division, or substitute thereof, or any equivalent of any of the foregoing, and
any patent issuing thereon, including any reissue, re-examination or extension
thereof.
1.29 "Product" shall mean any product for use in the Field containing an
Eligible Compound.
1.30 "Receiving Party" shall have the meaning given in Section 6.1.
1.31 "Screening Data" shall mean a summary report prepared by Tularik for
each JT Assay describing: [ * ].
1.32 "Screening Library" shall have the meaning given in the first
recital.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
3
1.33 "Screening Program" shall mean the program pursuant to which Tularik
will screen Compounds against JT Assays as described in Section 2.2.
1.34 "Screening Program Term" shall have the meaning given in Section 8.1.
1.35 "Screening Supplies" shall mean all biological materials, reagents or
special plates required for the screening of the JT Assay.
1.36 "Screening Technology" shall have the meaning given in the first
recital.
1.37 "Second Round Compounds" shall have the meaning given in Section
2.2.4.
1.38 "Second Round Results" shall have the meaning given in Section 2.2.5.
1.39 "Sublicensee" shall mean a Third Party to whom JT has granted a
sublicense under the Tularik Technology to make, use, develop, manufacture
and/or sell Product(s). As used in this Agreement, it is understood that
"Sublicensee" shall also include any Third Party to whom JT has granted the
right to distribute Product(s), provided that such Third Party has the primary
responsibility for marketing and promotion at its expense of such Product within
the field or territory for which such distribution rights are granted.
1.40 "Third Party" shall mean any person or entity other than Tularik and
JT, and their respective Affiliates.
1.41 "Third Round Compounds" shall have the meaning given in Section
2.2.6.
1.42 "Third Round Results" shall have the meaning given in Section 2.2.7.
1.43 "Tularik Inventions" shall have the meaning given in Section 5.1.1.
1.44 "Tularik Know-How" shall mean all ideas, inventions, data,
instructions, processes, formulas, expert opinion and information, including,
without limitation, biological, chemical, pharmacological, toxicological,
physical and analytical, safety, manufacturing and quality control data and
information, owned or Controlled, in whole or part, by Tularik during the
License Term by license, assignment or otherwise, in each case, necessary or
useful for the development or commercialization of Eligible Compounds, but shall
exclude Tularik Patent Rights.
1.45 "Tularik Library" shall have the meaning given in the first recital.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
4
1.46 "Tularik Patent Rights" shall mean Patent Rights owned, licensed or
Controlled by Tularik during the License Term that relate exclusively to
Eligible Compounds.
1.47 "Tularik Technology" shall mean Tularik Patent Rights and Tularik
Know-How.
2. Screening Activity.
2.1 Meetings. Tularik and JT will meet in person or communicate by
telephone or video conference as necessary during the Screening Program Term.
2.2 Screening.
2.2.1 Designation of JT Assay. Within [ * ] of the Effective Date,
JT shall propose in writing to Tularik at least [ * ] JT Assay for screening by
Tularik pursuant to this Agreement, as further described in the Attachment.
During the Screening Program Term, JT shall propose in writing to Tularik
additional JT Assays for screening by Tularik pursuant to this Agreement for a
total of [ * ] JT Assays per year and possibly [ * ] JT Assays per year if
expanded pursuant to this Section 2.2.1. Each year during the Screening Program
Term, Tularik shall use reasonable efforts to perform screening of [ * ] JT
Assays. During the Screening Program Term, JT may, upon written notice, request
that Tularik perform screening of [ * ] JT Assays per year, and Tularik may
perform such additional screening in its sole discretion. For each proposed JT
Assay, JT will provide Tularik with a written proposal describing such JT Assay.
Such written proposal shall include [ * ]. In addition to such written
proposal, JT shall provide to Tularik, or request Tularik to procure subject to
Section 4.4, at JT's discretion, all Screening Supplies. Within [ * ] following
receipt of such Screening Supplies, Tularik shall determine whether the JT Assay
is suitable for screening in a high throughput format. During such [ * ]
period, Tularik: [ * ]. Within [ * ] of receiving such proposal, and such
further information as Tularik may reasonably request regarding such proposed JT
Assay, Tularik shall notify JT in writing whether Tularik reasonably believes
that performing such JT Assay is [ * ]. In the event that Tularik reasonably
believes that performing such JT Assay is inconsistent with such Tularik
obligations or infeasible for the reasons set forth in the immediately preceding
sentence, Tularik shall not be obligated to accept such JT Assay for screening
pursuant to this Agreement.
2.2.2 Selection of Compounds. Within [ * ] of the Effective Date,
the Parties shall select an initial set of [ * ] Compounds from the Tularik
Library (the "Initial Compounds") that the Parties believe [*]. Anything in this
Section 2.2.2 to the contrary notwithstanding, the Initial Compounds selected by
the Parties shall consist of: [ * ].
2.2.3 Screening of Initial Compounds. Within: (a) [ * ] (in the
case of JT Assays that are [ * ]); or (b) the number of days (between [ * ])
determined by the
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
5
mutual agreement of the Parties (in the case of JT Assays that are [ * ]); of
receipt by Tularik of the payment set forth in Section 4.1(a), Tularik shall (i)
screen each Initial Compound to determine the [ * ] of such Initial Compound
with respect to the JT Target in the associated JT Assay and (ii) provide JT
with the Screening Data resulting therefrom for each of the Initial Compounds
with respect to the JT Target (the "Initial Results"). Within [ * ] of the
commencement of screening with respect to a given JT Target, Tularik will give
JT notice that such screening has commenced.
2.2.4 Initial Results. If JT determines that, based on the Initial
Results for a given JT Target, screening of additional Compounds in the Tularik
Library may be useful in relation to such JT Target, then based upon such
Initial Results, the Parties may select a set of up to [ * ] additional
Compounds from the Tularik Library (the "Second Round Compounds") that the
Parties believe will exhibit the greatest likelihood of an acceptable level of [
* ] in relation to such JT Target. Anything in this Section 2.2.4 to the
contrary notwithstanding, the Second Round Compounds selected by the Parties
shall consist of: [ * ].
2.2.5 Screening of Second Round Compounds. Within: (a) [ * ] (in the
case of JT Assays that are [ * ]); or (b) the number of days (between [ * ])
determined by the mutual agreement of the Parties (in the case of JT Assays that
are [ * ]); of receipt by Tularik of the payment set forth in Section 4.1(b),
Tularik shall: (i) screen each Second Round Compound to determine the level of
[ * ] of such Second Round Compound with respect to each JT Target; and (ii)
provide JT with the Screening Data resulting therefrom for each of the Second
Round Compounds (the "Second Round Results").
2.2.6 Second Round Results. If JT determines that, based on the
Initial Results and the Second Round Results for a given JT Target, screening of
additional Compounds in the Tularik Library may be useful in relation to such JT
Target, then based upon the Initial Results and Second Round Results, the
Parties may select a set of up to [ * ] additional Compounds from the Tularik
Library (the "Third Round Compounds") that the Parties believe will exhibit the
greatest likelihood of an acceptable level of [ * ] in relation to such JT
Target. Anything in this Section 2.2.6 to the contrary notwithstanding, the
Third Round Compounds selected by the Parties shall consist of: [ * ].
2.2.7 Screening of Third Round Compounds. Within: (a) [ * ] (in the
case of JT Assays that are [ * ]); or (b) the number of days (between [ * ])
determined by the mutual agreement of the Parties (in the case of JT Assays that
are [ * ]); of receipt by Tularik of the payment set forth in Section 4.1(c),
Tularik shall: (i) screen each Third Round Compound to determine the level of [
* ] of such Third Round Compound with respect to each JT Target; and (ii)
provide JT with the Screening Data resulting therefrom for each of the Third
Round Compounds (the "Third Round Results"). Subject to Section 3.8, Tularik
shall immediately remove from Tularik's library each Eligible Compound upon
selection thereof by JT.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
6
2.3 Record-Keeping. Tularik shall maintain records, in sufficient detail
and in a good scientific manner, which shall reflect all work performed and
results obtained in performance of JT Assay (including all data in the form
required under all applicable laws and regulations of the United States).
3. Transfer of Rights.
3.1 Rights to JT. Subject to the terms and conditions of this Agreement,
Tularik hereby: (i) assigns to JT all right, title and interest in the Tularik
Patent Rights; (ii) grants to JT an exclusive, worldwide, fully-paid up,
royalty-free license under the Tularik Inventions and the interest of Tularik in
the Joint Technology; and (iii) grants to JT a nonexclusive, worldwide, fully-
paid up, royalty-free license under the Tularik Know-How; to make, have made and
use Eligible Compounds, to develop, make, have made, use, sell, have sold, offer
for sale, import and have imported Products in the Field. Anything in this
Agreement to the contrary notwithstanding, any Eligible Compound for which JT
has not made any required payment pursuant to Section 4.2 and/or 4.3 shall not
be a Eligible Compound for the purpose of the foregoing assignment and licenses;
provided, however, that [ * ].
3.2 License to Tularik. Subject to the terms and conditions of this
Agreement, JT grants to Tularik, on a JT Assay-by-JT Assay basis, a non-
transferable, nonexclusive, license under JT Technology, without the right to
grant sublicenses, to make and use any JT Assay solely in connection with the
conduct of the Screening Program.
3.3 Retained Rights. Except for the licenses expressly provided in
Section 3.1 and 3.2, no right or license in or to any intellectual property
owned or Controlled by JT or Tularik, as the case may be, is granted or implied
hereunder, and each Party shall retain all rights not expressly granted to the
other Party. No license or other right in the Tularik Technology or JT
Technology shall be created hereunder by implication, estoppel or otherwise.
Notwithstanding the licenses and rights granted to JT herein, Tularik retains
the right to make, have made and use all Compounds other than Eligible Compounds
selected by JT pursuant to Section 3.7 for any purpose.
3.4 Sublicenses. Subject to the terms and conditions of this Agreement,
JT shall have the right to sublicense the rights granted in Section 3.1(ii) and
(iii) above. Each such sublicense shall be consistent with all the terms and
conditions of this Agreement and subordinate to this Agreement. Each such
sublicense of the rights granted in: (i) Section 3.1(ii) shall be subject to
the receipt by Tularik of prior written notice from JT; and (ii) Section
3.1(iii) shall be subject to the prior consent of Tularik, which consent shall
not be unreasonably withheld. JT shall remain responsible to Tularik for all of
each such Sublicensee's applicable obligations under the sublicense. Each
sublicense shall provide for the continuation of the license following early
termination of the license rights of JT hereunder.
3.5 Third Party Rights.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
7
3.5.1 Overlapping Rights. It is understood that Tularik is in the
business of providing screening services to Third Parties, and that Tularik will
grant such Third Parties rights after the Effective Date to acquire licenses for
Compounds similar to JT's rights under this Agreement. Notwithstanding the
licenses granted to JT above, it is possible that a Third Party may acquire
rights from Tularik with respect to one or more Compounds of which Tularik is a
sole or joint owner; accordingly, Tularik's grant of rights in this Article 3 is
limited to the extent that a Third Party (either alone or jointly with Tularik)
has filed a patent application with respect to such a Compound prior to the
filing by JT (either alone or jointly with Tularik) of a patent application with
respect to such a Compound. It is further understood that Compounds provided to
Third Parties in the course of Tularik's other business activities may result in
Third Party patent applications and patents that could affect the rights granted
to JT under this Article 3. Notwithstanding the foregoing, JT shall have the
right: [ * ]. In any event, Tularik shall immediately advise JT of any Highly
Active Compounds of which Tularik is aware at any time during the License Term
as being the subject of any patent or patent application of any such Third
Party. Anything in this Section 3.5.1 to the contrary notwithstanding, Tularik
covenants and agrees that it shall not, following the License Commencement Date,
[ * ].
3.5.2 No Liability. It is understood and agreed that, even if
Tularik complies with its obligations under this Agreement, Compounds provided
to Third Parties in the course of Tularik's other business activities may result
in Third Party patent applications and patents, including patent applications
and patents owned by such Third Parties, or owned jointly by Tularik and such
Third Parties, that could conflict with patent applications and patents owned by
JT, or jointly owned by JT and Tularik hereunder. Tularik will use its
reasonable efforts to avoid such conflict and, [ * ] Tularik shall have no
liability under this Agreement with respect to any such conflict, except as set
forth in Section 4.9 hereof.
3.6 No Other Products. Except as otherwise agreed by Tularik in writing,
neither JT nor its Affiliates or Sublicensees shall commercialize (or authorize
the commercialization of) any Eligible Compound other than as a Product in
accordance with this Agreement.
3.7 Limitation on Rights to Eligible Compounds. In the event that the
Screening Program results in a universe of potentially Eligible Compounds that
exceeds [ * ] Eligible Compounds, JT shall have the ability to select from among
such universe those [ * ] Eligible Compounds of greatest interest to JT in its
sole discretion. Such selection shall be made following the receipt by JT of
the Initial Results, the Second Round Results or the Third Round Results, as the
case may be. The license granted, and the rights assigned, pursuant to Section
3.1 shall be [ * ] pursuant to this Section 3.7.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
8
3.8 Removal of Eligible Compounds. Tularik shall remove from the Tularik
Library during the License Term each Eligible Compound that has been selected by
JT pursuant to Section 3.7 up to an aggregate of [ * ] such Eligible Compounds.
3.9 Value of Know-How; Convenience of the Parties. The Parties
acknowledge that Tularik may not own or control patent applications or patents
covering the manufacture, sale or use of a particular Product. However, the
Parties agree that, in addition to the value of the license under Section 3.1
because of such patents (if any), substantial value is contributed by Tularik
under this Agreement in accelerated time to market, enhanced probability of
success and the potential for multiple leads. For the convenience of the
Parties, JT agrees to pay the amount specified herein, regardless of whether a
Product is covered by a patent application or patent owned or Controlled by
Tularik.
3.10 Third Party Royalties. JT shall be responsible for the payment of any
royalties due to Third Parties for the manufacture, use or sale of Products by
JT, its Affiliates or Sublicensees.
4. Payments.
4.1 Screening Payments. In consideration for Tularik's performance of the
Screening Program in accordance with Section 2.2 for each JT Assay, JT will pay
to Tularik (a) [ * ] for the Initial Compounds selected by the Parties for
screening against such JT Assay pursuant to Section 2.2.2; (b) [ * ] for the
Second Round Compounds selected for screening against such JT Assay by the
Parties pursuant to Section 2.2.4; and (c) [ * ] for the Third Round Compounds
selected for screening against such JT Assay by the Parties pursuant to Section
2.2.6. Upon receipt of such payment, Tularik will proceed with testing
Compounds in such Screening Program pursuant to Section 2.2.
4.2 High Activity Compound Payments.
4.2.1 High Activity Compound Fee. Subject to the [ * ] set forth in
Section 4.2.2, for each High Activity Compound for a given JT Target for which
rights are granted to JT pursuant to Section 3.1, JT will pay to Tularik [ * ].
Such payment shall be made by JT to Tularik promptly following JT's independent
confirmation that each High Activity Compound referenced in the Initial Results,
Second Round Results or Third Round Results, as the case may be, exhibits [ * ]
with respect to the relevant JT Target in the JT Assay at the [ * ] specified in
accordance with Section 1.10(b). JT shall endeavor to complete such independent
confirmation within a period of [ * ] commencing on the receipt of such High
Activity Compound from Tularik or another source, as provided herein. JT may
request that Tularik provide JT with such High Activity Compound to accomplish
such independent confirmation. Tularik shall use its reasonable efforts to
provide to JT [ * ] of such High Activity Compound [ * ] for this purpose;
provided, however, [ * ]. In the event Tularik [ * ] such High Activity
Compound pursuant to the foregoing proviso, JT shall [ * ] such High Activity
Compound or give up the rights granted in Section 3.1 in such High Activity
Compound.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
9
In the event JT elects [ * ] such High Activity Compound, JT shall endeavor to
complete such [ * ] within a reasonable time. Tularik shall use its reasonable
efforts to provide JT with such information and/or data requested by JT as is
reasonably necessary to permit JT to perform such [ * ].
4.2.2 [ * ] High Activity Compound License Fee. In the event that
there are more than [ * ] Compounds that are High Activity Compounds for a given
JT Target, JT shall not be obligated to [ * ] under Section 4.2.1 for such JT
Target.
4.3 Payments for Compounds that are not High Activity Compounds. For each
Compound that JT desires to license pursuant to Section 3.1, notwithstanding
that such Compound is not a High Activity Compound, JT will pay to Tularik,
within [ * ] of the date on which each such Compound is selected by JT: (a) [ *
] such Compounds licensed pursuant to this Section 4.3; and (b) [ * ] for each
such Compound in excess of [ * ] Compounds licensed pursuant to this Section
4.3.
4.4 Payments for New Capital Equipment and Screening Supplies. In the event
that new capital equipment [ * ] is required by Tularik in order to screen the
JT Assays, Tularik shall forward to JT in writing the relevant information and
costs therefor in advance. In the event JT agrees to the purchase of such
equipment and/or Screening Supplies, [ * ]. [ * ].
4.5 Payments. Any payments due pursuant to Sections 4.1, 4.2, 4.3 or 4.4
shall be paid within [ * ] of receipt of an invoice therefor.
4.6 Payment Method. All payments due under this Agreement shall be made by
bank wire transfer when due in immediately available funds to an account
designated by Tularik. Any payments that are not paid on the date such payments
are due under this Agreement shall bear interest to the extent permitted by
applicable law at the [ * ] per annum, calculated on the number of days such
payment is delinquent.
4.7 Currency Conversion. All payments outlined in this Agreement are in
U.S. Dollars. If any currency conversion shall be required in connection with
the calculation of any payments hereunder, such conversion shall be made using
the selling exchange rate for conversion of the foreign currency into U.S.
Dollars, quoted for current transactions as reported in The Wall Street Journal
for the last reported day of the calendar quarter to which such payment
pertains.
4.8 Tax Matters. All amounts required to be paid to Tularik pursuant to
this Agreement shall be paid without deduction for withholding for or on account
of any taxes, including any sales, use, value added or transfer tax, or similar
governmental charge imposed by a jurisdiction other than the United States.
Payment of any such tax or similar governmental charge, including any due in
connection with the transfer of the JT Assays hereunder, shall be the sole
responsibility of JT. In the event that Tularik is required to pay any such tax
or other similar charge, JT shall promptly reimburse Tularik for payment of such
amounts.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
10
4.9 Refunds or Credits. Except as expressly provided below, any payment
made to Tularik pursuant to this Agreement shall be non-refundable. Payments
made by JT to Tularik for any Highly Active Compounds pursuant to Section 4.2.1,
or for any Compounds that are not Highly Active Compounds pursuant to Section
4.3, for which [ * ] shall be refunded in full by Tularik to JT and the license
set forth in Section 4.2.1 or 4.3, as the case may be, shall terminate.
5. Ownership of Inventions.
5.1 Ownership.
5.1.1 Sole Ownership. JT shall be the sole owner of all intellectual
property conceived and reduced to practice or otherwise developed solely by its
employees and agents, and all patent applications and patents claiming such
intellectual property arising out of the Screening Program or JT's use thereof
("JT Inventions"). Tularik shall be the sole owner of any intellectual property
conceived and reduced to practice or otherwise developed solely by its employees
and agents and all patent applications and patents claiming such intellectual
property arising out of the Screening Program ("Tularik Inventions"); provided,
however, that any Tularik Invention that relates primarily to the JT Assays
shall be assigned to JT. Each Party agrees to execute, or have its employees,
agents or consultant execute, all paperwork necessary to effectuate any such
assignment necessary to achieve such ownership by Tularik or JT, as the case may
be.
5.1.2 Joint Technology. If, during the Screening Program, one or more
employees or consultants of Tularik, together with one or more employees or
consultants of JT, jointly conceive any intellectual property (the "Joint
Technology"), each of the Parties shall own an undivided one-half interest in
the Joint Technology.
5.1.3 U.S. Law. Inventorship of Tularik Inventions, JT Inventions and
Joint Technology shall be determined in accordance with the patent laws of the
United States.
5.1.4 Retained Rights. Except as otherwise expressly provided in this
Agreement, nothing in this Agreement is intended to convey or transfer ownership
by one Party to the other of any right, title or interest in any Confidential
Information, Inventions or Patent Rights owned or Controlled by a Party. Except
as expressly provided for in this Agreement, nothing in this Agreement shall be
construed as a license or sublicense by one Party to the other of any rights in
any Inventions or Patent Rights owned or Controlled by a Party or its
Affiliates.
5.2 Patent Filing and Prosecution.
5.2.1 Cooperation. JT and Tularik shall consult together upon all
matters relating to the filing, prosecution, and maintenance of patents within
Joint
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
11
Technology. This shall include giving the other Party the opportunity to review
and comment upon the text of any priority application before filing;
consultation about the decision whether or not to foreign file and, if so, in
which countries; and giving the other Party the opportunity, as far in advance
of filing dates as feasible, to fully review and comment on the basic foreign
filing text. Each Party shall provide to the other copies of any search reports
and official actions, including notice of all interferences, reissues, re-
examinations, and oppositions received from the relevant patent offices promptly
after receipt. Each Party shall reasonably cooperate with and assist the other
in connection with activities subject to this Section 5.2.1, at the other's
request. Each Party shall execute, and ensure that its employee inventors shall
execute, all documents reasonably required in connection with the filing,
prosecution or maintenance of patents within the Joint Technology. Patent
counsel designated by each Party will meet in person or by telephone or video
conference as necessary during (i) the Screening Program Term, and (ii) the
pendency of any of the patent applications within the scope of this Section
5.2.1 to coordinate, discuss, review and implement patent filing and prosecution
strategy. In the event that a single patent or patent application within Tularik
Patent Rights contains both Eligible Compounds and other Compounds, Tularik
shall file a divisional application directed exclusively to the Eligible
Compounds in a timely and commercially reasonable manner.
5.2.2 Failure to Prosecute. Either Party may elect upon sixty (60)
days prior notice to discontinue prosecution or maintenance of any patent within
Joint Technology in any or all countries. In such case, the other Party shall
have the right to prosecute and maintain such patent applications and patents in
such countries it deems appropriate, at its sole expense.
5.3 Enforcement. JT and Tularik shall separately have the right, but not
the obligation, to bring proceedings against any Third Party for the
inappropriate use, including patent infringement, of Inventions, trade secrets
or Patent Rights solely owned or Controlled by it, and at its own risk and
expense. Such Party shall be entitled to retain any and all awards or damages
obtained in any such proceeding. At the request and expense of either Party, the
other Party shall give the requesting Party all reasonable assistance required
to file and conduct any such proceeding. For Joint Technology, JT and Tularik
shall use their best efforts to coordinate pursuing a commercially reasonable
action to address inappropriate use, including patent infringement, by Third
Parties of such Joint Technology and to determine how expenses and any recovery
from such action shall be allocated between the Parties.
5.4 Defense of Infringement Claims.
5.4.1 Claims Relating to Products. Tularik will cooperate with JT, at
JT's request and expense, in the defense of any suit, action or proceeding
against Tularik and its Affiliates, or JT and its Affiliates or Sublicensees,
alleging the infringement of the intellectual property rights of a Third Party
by reason of the manufacture, use or sale of a Product by JT, its Affiliates or
Sublicensees. JT shall give Tularik prompt written notice
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
12
of the commencement of any such suit, action, proceeding or claim of
infringement. Tularik shall give to JT all authority, information and assistance
necessary to defend or settle any such suit, action or proceeding; provided,
however, that if Tularik or its Affiliates should be joined in any such suit,
action or proceeding pursuant to this Section 5.4.1 at the request of JT, JT
shall [ * ]. JT shall have the right to control the conduct and settlement of
any such litigation; provided, however, that [ * ].
5.4.2 Claims Relating to Tularik Technology. JT will cooperate with
Tularik, at Tularik's expense, in the defense of any suit, action or proceeding
against Tularik or its Affiliates alleging the infringement of the intellectual
property rights of a Third Party by reason of Tularik's use of any Tularik
Patent Rights and Tularik Technology (other than Products) in performing its
obligations to JT under this Agreement. Tularik shall give JT prompt written
notice of the commencement of any such suit, action, proceeding or claim of
infringement. JT shall give to Tularik all authority, information and assistance
necessary to defend or settle any such suit, action or proceeding; provided,
however, that if JT should be joined in any such suit, action or proceeding
pursuant to this Section 5.4.2 at the request of Tularik, Tularik shall [ * ].
5.5 Indemnity. JT shall indemnify, defend and hold harmless Tularik from
any and all damages, costs or expenses arising out of any: [ * ] (without regard
to the nature of the causes of action alleged or theories of recovery asserted)
arising in connection with the development and/or commercialization of Products
by JT, its Affiliates or Sublicensees; except to the extent caused by [ * ].
6. Confidential Information.
6.1 Nondisclosure Obligations. Subject to the provisions of Section 6.2
below, during the later of Screening Program Term or License Term and for [ * ]
years thereafter, any and all knowledge, know-how, screening results, assay
information, Compound structures, practices, processes or other information
received by one Party to this Agreement (the "Receiving Party") from the other
Party to this Agreement (the "Disclosing Party") pursuant to this Agreement
(hereinafter referred to as "Confidential Information") shall be received and
maintained by the Receiving Party in strict confidence, shall not be disclosed
to any Third Party, and shall not be used by the Receiving Party for any purpose
other than those purposes specified in this Agreement, unless the Receiving
Party can demonstrate by competent written proof that such Confidential
Information:
(a) was already known to the Receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the Disclosing
Party;
(b) was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the Receiving Party;
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
13
(c) became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act of omission of
the Receiving Party in breach of this Agreement;
(d) was disclosed to the Receiving Party, other than under an
obligation of confidentiality to a Third Party, by a Third Party who had no
obligation to the Disclosing Party not to disclose such information to others;
(e) was independently discovered or developed by the Receiving Party
without the use of Confidential Information belonging to the Disclosing Party;
or
(f) [ * ].
6.2 Authorized Disclosure. Each Party may disclose Confidential
Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances:
(a) filing or prosecuting patents relating to inventions;
(b) prosecuting or defending litigation;
(c) complying with applicable governmental regulations;
(d) disclosure to Affiliates, Sublicensees, employees,
consultants or agents each of whom is bound by similar terms of confidentiality
and non-use at least equivalent in scope to those set forth in this Article 6;
and,
(e) disclosure to investment bankers.
Notwithstanding the foregoing, in the event a Party is required to make a
disclosure of the other Party's Confidential Information pursuant to this
Section 6.2 it will, except where impracticable, give reasonable advance notice
to the other Party of such disclosure and use best efforts to take all
reasonable action to avoid disclosure of Confidential Information hereunder.
Further, JT shall have the right to use all information received with respect to
Highly Active Compounds hereunder for purposes relating to such Highly Active
Compounds' development and commercialization.
7. Representations and Warranties.
7.1 By JT. JT represents and warrants to Tularik that it has the right to
provide the JT Assays to be supplied hereunder and that it has not previously
entered and will not enter during the Screening Period Term into any agreement
with a Third Party in conflict with this Agreement.
7.2 By Tularik. Tularik represents and warrants to JT that it has the
right to carry out the activities under Article 2 above and that it has not
previously entered and
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
14
will not enter during the Screening Period Term into any agreement with a Third
Party in conflict with this Agreement.
7.3 Disclaimer Concerning Compounds. THE COMPOUNDS AND ANY CHEMICAL
STRUCTURES DISCLOSED TO JT HEREUNDER ARE BEING PROVIDED WITH NO WARRANTIES OF
ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE OR THAT THEY ARE FREE FROM THE RIGHTFUL CLAIM
OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE. NOTWITHSTANDING THE
FOREGOING, TULARIK WARRANTS AND REPRESENTS THAT IT IS NOT, AS OF THE EFFECTIVE
DATE, AWARE OF ANY EXISTING THIRD PARTY CLAIMS AGAINST OR WITH RESPECT TO THE
COMPOUNDS.
8. Term; Termination.
8.1 Term. This Agreement shall become effective as of the Effective Date
and, unless earlier terminated as hereinafter provided, shall continue in force
for a period of two (2) years after the same ("Screening Program Term"). The
Screening Program Term may be extended for additional periods from time to time
upon mutual agreement of the Parties hereto.
8.2 Termination for Default. In the event that either Party to this
Agreement shall be in default of any of its material obligations hereunder and
shall fail to remedy such default within [ * ] after receipt of written notice
thereof, the Party not in default shall have the option of terminating this
Agreement by giving written notice thereof, notwithstanding anything to the
contrary contained in this Agreement.
9. Accrued Rights; Surviving Obligations
9.1 Termination of this Agreement shall not affect any accrued rights of
either Party. The terms of Section 3.1(i), 3.1(iii), 3.5.1, 3.5.2, 11.4 and
Articles 5, 6 and 7 of this Agreement shall survive termination of this
Agreement. Promptly after termination of this Agreement each Party shall return
or dispose of any materials and information of the other in accordance with the
instructions of the other, including without limitation any Compounds and
written materials disclosed hereunder.
10. Governing Law; Dispute Resolution.
10.1 Governing Law. This Agreement shall be governed by and construed in
accordance with the domestic laws of the State of New York without giving effect
to any choice or conflict of law provision or rule that would cause the
application of the laws of any jurisdiction other than the State of California.
10.2 Dispute Resolution. In the event of any controversy or claim arising
out of, relating to or in connection with any provision of this Agreement, the
Parties shall try to settle their differences amicably and in good faith between
themselves first, by
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
15
referring the disputed matter to the respective heads of research of each Party
and, if not resolved by the research heads, by referring the disputed matter to
the respective Chief Executive Officers of each Party.
11. Miscellaneous.
11.1 Notices. All notices required or permitted to be given under this
Agreement shall be in writing and shall be mailed by registered or certified
airmail, postage prepaid, addressed to the signatory to whom such notice is
required or permitted to be given or transmitted by facsimile to the number
indicated below. All notices shall be deemed to have been given when mailed, as
evidenced by the postmark at the point of mailing, or transmitted by facsimile.
All notices to JT shall be addressed as follows:
Japan Tobacco Inc.
Central Pharmaceutical Research Institute
0-0, Xxxxxxxx-xxx, Xxxxxxxxx, Xxxxx 000-0000
Xxxxx
Fax: 00-000-00-0000
Attn: [ * ]
[ * ]
with a copy to:
Japan Tobacco Inc.
Pharmaceutical Division-
Japan Tobacco Xxxx.
0-0, Xxxxxxxxx 0-xxxxx, Xxxxxx-xx, Xxxxx 000-0000
Fax: 00-0-0000-0000
Attn: [ * ]
[ * ]
All notices to Tularik shall be addressed as follows:
Tularik Inc.
Xxx Xxxxxxxxx Xxxxx
Xxxxx Xxx Xxxxxxxxx, XX 00000 U.S.A.
Attn.: President
Any Party may, by written notice to the other, designate a new addressee,
address or facsimile number to which notices to the Party giving the notice
shall thereafter be mailed or faxed.
11.2 Independent Contractors. The Parties shall perform their obligations
under this Agreement as independent contractors and nothing contained in this
Agreement shall be construed to be inconsistent with such relationship status.
This
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
16
Agreement shall not constitute, create or in any way be interpreted as a joint
venture or partnership of any kind.
11.3 Entire Agreement; Amendment. This Agreement sets forth all the
covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties hereto and supersedes and terminates all
prior agreements and understandings between the Parties hereto with regard to
the subject matter hereof, and there are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or
written, between the Parties hereto other than as set forth herein. No
subsequent alteration, amendment, change or addition to this Agreement shall be
binding upon the Parties hereto unless reduced to writing and signed by the
respective authorized officers of the Parties hereto.
11.4 Arbitration. Any dispute or claim arising out of or related to this
Agreement, or the interpretation, making, performance, breach, validity, or
termination hereof, that has not been resolved by negotiation or mediation as
set forth above, shall be finally settled by binding arbitration in accordance
with the Rules of Conciliation and Arbitration of the International Chamber of
Commerce ("ICOC Rules") by one arbitrator appointed in accordance with the ICOC
Rules. The arbitration proceedings shall be [ * ]. At the request of either
Party, the arbitrator will enter an appropriate protective order to maintain the
confidentiality of information produced or exchanged in the course of the
arbitration proceedings. The judgment of the arbitrator shall be in the form of
a reasoned, written opinion, and shall be issued within sixty (60) days of the
conclusion of the arbitration proceeding. Any award rendered by the
arbitrator(s) shall be conclusive and binding upon the parties, and may be
entered in any court having jurisdiction thereof. The Parties may apply to any
court of competent jurisdiction for a temporary restraining order, preliminary
injunction, or other interim relief, as necessary, without breach of this
arbitration provision and without any abridgment of the powers of the
arbitrator. The arbitrator may award to the prevailing Party, if any, as
determined by the arbitrator, its costs and fees, including, without limitation,
ICOC administrative fees, arbitrator fees, travel expenses, out-of-pocket
expenses, witness fees, and reasonable attorneys' fees. In the absence of such
an award, each party shall bear its own costs and fees associated with such
arbitration.
11.5 Affiliates; Assignment. Except as otherwise provided in this Section
11.5, neither Party may assign its rights or obligations under this Agreement
without the prior written consent of the other Party, such consent not to be
unreasonably withheld, except that a Party may assign its rights or obligations
to a Third Party in connection with the merger, consolidation, reorganization or
acquisition of stock or assets affecting substantially all of the assets or
actual voting control of the assigning Party. This Agreement shall be binding
upon the successors and permitted assigns of the Parties. Any attempted
delegation or assignment not in accordance with this Section 11.5 shall be of no
force or effect.
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
17
11.6 Headings. The headings used in this Agreement are for convenience of
reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement.
11.7 Force Majeure. Any delays in performance by any Party under this
Agreement shall not be considered a breach of this Agreement if and to the
extent caused by occurrences beyond the reasonable control of the Party
affected, including but not limited to, acts of God, embargoes, governmental
restrictions, strikes or other concerted acts of workers, fire, flood,
explosion, riots, wars, civil disorder, rebellion or sabotage. The Party
suffering such occurrence shall immediately notify the other Party and any time
for performance hereunder shall be extended by the actual time of delay caused
by the occurrence.
11.8 Severability. If any term, condition or provision of this Agreement
is held to be unenforceable for any reason, it shall, if possible, be
interpreted rather than voided, in order to achieve the intent of the Parties to
this Agreement to the extent possible. In any event, all other terms, conditions
and provisions of this agreement shall be deemed valid and enforceable to the
full extent.
11.9 Waiver. None of the terms, covenants, and conditions of this
Agreement can be waived except by the written consent of the Party waiving
compliance.
11.10 English Language. This Agreement has been prepared in the English
language and shall be construed in the English language.
In Witness Whereof, the Parties have by duly authorized persons, executed
this Agreement, as of the date first above written.
Japan Tobacco Inc. Tularik Inc.
By: /s/ Y. Inubushi By: /s/ Xxxx X. XxXxxxxxxx
----------------------------- -------------------------
Title: Vice President, International Development Title: President
Date: September 9, 1999 Date: August 23, 1999
--------------------------- -----------------------
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
18
